Vietnam · Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 8.47 trillion. The enterprise value is 8.33 trillion.
| Market Cap | 8.47T |
| Enterprise Value | 8.33T |
Important Dates
The last earnings date was Friday, July 18, 2025.
| Earnings Date | Jul 18, 2025 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -1.90% in one year.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | -1.90% |
| Shares Change (QoQ) | +39.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.26% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 25.72.
| PE Ratio | 25.72 |
| Forward PE | n/a |
| PS Ratio | 3.50 |
| PB Ratio | 3.99 |
| P/TBV Ratio | 4.14 |
| P/FCF Ratio | 349.92 |
| P/OCF Ratio | 113.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.72, with an EV/FCF ratio of 344.16.
| EV / Earnings | 25.30 |
| EV / Sales | 3.44 |
| EV / EBITDA | 14.72 |
| EV / EBIT | 17.99 |
| EV / FCF | 344.16 |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.63 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.71 |
| Debt / FCF | 16.71 |
| Interest Coverage | 43.63 |
Financial Efficiency
Return on equity (ROE) is 17.04% and return on invested capital (ROIC) is 12.31%.
| Return on Equity (ROE) | 17.04% |
| Return on Assets (ROA) | 10.47% |
| Return on Invested Capital (ROIC) | 12.31% |
| Return on Capital Employed (ROCE) | 19.46% |
| Revenue Per Employee | 1.67B |
| Profits Per Employee | 226.78M |
| Employee Count | 1,452 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.86 |
Taxes
In the past 12 months, Imexpharm has paid 95.73 billion in taxes.
| Income Tax | 95.73B |
| Effective Tax Rate | 21.11% |
Stock Price Statistics
The stock price has increased by +29.56% in the last 52 weeks. The beta is 0.77, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +29.56% |
| 50-Day Moving Average | 52,010.00 |
| 200-Day Moving Average | 47,729.00 |
| Relative Strength Index (RSI) | 62.91 |
| Average Volume (20 Days) | 231,642 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.42 trillion and earned 329.28 billion in profits. Earnings per share was 2,138.06.
| Revenue | 2.42T |
| Gross Profit | 1.14T |
| Operating Income | 463.00B |
| Pretax Income | 453.50B |
| Net Income | 329.28B |
| EBITDA | 565.83B |
| EBIT | 463.00B |
| Earnings Per Share (EPS) | 2,138.06 |
Balance Sheet
The company has 544.02 billion in cash and 404.56 billion in debt, giving a net cash position of 139.46 billion or 905.54 per share.
| Cash & Cash Equivalents | 544.02B |
| Total Debt | 404.56B |
| Net Cash | 139.46B |
| Net Cash Per Share | 905.54 |
| Equity (Book Value) | 2.12T |
| Book Value Per Share | 13,779.33 |
| Working Capital | 1.06T |
Cash Flow
In the last 12 months, operating cash flow was 74.63 billion and capital expenditures -50.42 billion, giving a free cash flow of 24.21 billion.
| Operating Cash Flow | 74.63B |
| Capital Expenditures | -50.42B |
| Free Cash Flow | 24.21B |
| FCF Per Share | 157.18 |
Margins
Gross margin is 47.15%, with operating and profit margins of 19.10% and 14.76%.
| Gross Margin | 47.15% |
| Operating Margin | 19.10% |
| Pretax Margin | 18.71% |
| Profit Margin | 14.76% |
| EBITDA Margin | 23.35% |
| EBIT Margin | 19.10% |
| FCF Margin | 1.00% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.91%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.91% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 19.57% |
| Buyback Yield | 1.90% |
| Shareholder Yield | 2.83% |
| Earnings Yield | 3.89% |
| FCF Yield | 0.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 6.6 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.6 |
| Piotroski F-Score | 4 |